The content on this site is intended for healthcare professionals only
Dr Fehrenbacher speaks with ecancer at SABCS 2017 about a phase III trial of adjuvant chemotherapy with or without trastuzumab for HER2low invasive breast cancer.
Building on findings for high HER2 patients, Dr Fehrenbacher sets out the rationale for investigating HER2 low and negative patients, as scored by FISH or IHC.
Ultimately, trial findings were negative, with trastuzumab offering no improvement for invasive disease free survival.
Watch the press conference for more.
The added value of integrative medicine
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
The current status of multiple myeloma diagnosis and treatment
